Study study type
PathologyT1T0Patientssample sizesROB Results

la/mBC - HER2 positive - 1st Line (L1) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 1st Line (L1)

versus trastuzumab plus docetaxel
pertuzumab plus trastuzumab plus docetaxel
PUFFIN, 2020
  NCT02896855		RCTla/mBC - HER2 positive - 1st Line (L1)pertuzumab plus trastuzumab plus docetaxelplacebo plus trastuzumab plus docetaxelPatients with HER2-positive, locally recurrent or metastatic BC, no prior therapy for metastatic disease, 18yr or older.-/-NA
 suggested
  • suggested 31 % decrease in progression or deaths (PFS)
CLEOPATRA, 2012
  NCT00567190		RCTla/mBC - HER2 positive - 1st Line (L1)pertuzumab plus trastuzumab plus docetaxelplacebo plus trastuzumab plus docetaxelPatients with locally recurrent, unresectable, or metastatic HER2-positive breast cancer who had not received chemotherapy or biologic therapy for their metastatic disease. They may have received one hormonal treatment for metastatic breast cancer before randomization, and/or adjuvant or neoadjuvant chemotherapy with or without trastuzumab before randomization402 / 406low
 conclusif
  • demonstrated 34 % decrease in deaths (OS) (PE)
  • demonstrated 38 % decrease in progression or deaths (PFS) (PE)
  • suggested 31 % decrease in deaths (OS) (extension)
  • suggested 31 % decrease in PFS (extension)
    • more...

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons